Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > Private Placement

<< Previous

Bullboard Posts

Next >>

Comment by Genie29jon Jul 08, 2022 6:40pm

108 Views

Post# 34812223

RE:RE:RE:Private Placement

Well no matter what, we should hear back on the conclusion of the arbitration with Shiseido by mid-Oct. that will be here before we know it.

But this is bad news, they will run out of cash at this rate very quickly. They are desperate...if not now, soon. Very soon

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario